{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T18:36:29Z","timestamp":1789497389688,"version":"build-2803163510"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-025-01362-1","type":"journal-article","created":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T11:16:39Z","timestamp":1760613399000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Sex-specific dysregulation of exosomal non-coding RNAs drives multiple myeloma progression"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0691-4722","authenticated-orcid":false,"given":"Samaneh","family":"Maleknia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanam","family":"Rezaei Benam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg","family":"Ahmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5938-3769","authenticated-orcid":false,"given":"Rafael","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane F.","family":"Jelinek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0816-0733","authenticated-orcid":false,"given":"Reza","family":"Shahbazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,16]]},"reference":[{"key":"1362_CR1","doi-asserted-by":"crossref","unstructured":"Bolli N, Martinelli G, Cerchione C. The molecular pathogenesis of multiple myeloma. Hematol Rep. 2020;12:9054.","DOI":"10.4081\/hr.2020.9054"},{"key":"1362_CR2","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.146","volume":"3","author":"P Yang","year":"2022","unstructured":"Yang P, Qu Y, Wang M, Chu B, Chen W, Zheng Y, et al. Pathogenesis and treatment of multiple myeloma. MedComm. 2022;3:e146.","journal-title":"MedComm"},{"key":"1362_CR3","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1002\/jha2.470","volume":"3","author":"A Dweik","year":"2022","unstructured":"Dweik A, Dweik H, Mian H, Mohan M, Schinke C, Al Hadidi S. Gender disparities in multiple myeloma publications. EJHaem. 2022;3:966\u20139.","journal-title":"EJHaem"},{"key":"1362_CR4","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.ccell.2016.04.001","volume":"29","author":"Y Yuan","year":"2016","unstructured":"Yuan Y, Liu L, Chen H, Wang Y, Xu Y, Mao H, et al. Comprehensive characterization of molecular differences in cancer between male and female patients. Cancer Cell. 2016;29:711\u201322.","journal-title":"Cancer Cell"},{"key":"1362_CR5","first-page":"213","volume":"52","author":"L Gabriele","year":"2016","unstructured":"Gabriele L, Buoncervello M, Ascione B, Bellenghi M, Matarrese P, Car\u00e8 A. The gender perspective in cancer research and therapy: novel insights and on-going hypotheses. Ann Dell\u2019istituto Super Di Sanita. 2016;52:213\u201322.","journal-title":"Ann Dell\u2019istituto Super Di Sanita"},{"key":"1362_CR6","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.3389\/fonc.2019.01513","volume":"9","author":"S Wang","year":"2020","unstructured":"Wang S, Xu L, Feng J, Liu Y, Liu L, Wang J, et al. Prevalence and incidence of multiple myeloma in urban area in China: a national population-based analysis. Front Oncol. 2020;9:1513.","journal-title":"Front Oncol"},{"key":"1362_CR7","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/sj.bmt.1704861","volume":"35","author":"G Gahrton","year":"2005","unstructured":"Gahrton G, Iacobelli S, Apperley J, Bandini G, Bj\u00f6rkstrand B, Blad\u00e9 J, et al. The impact of donor gender on outcome of allogeneic hematopoietic stem cell transplantation for multiple myeloma: reduced relapse risk in female to male transplants. Bone Marrow Transplant. 2005;35:609\u201317.","journal-title":"Bone Marrow Transplant"},{"key":"1362_CR8","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1158\/1055-9965.EPI-11-0157","volume":"20","author":"KD Boyd","year":"2011","unstructured":"Boyd KD, Ross FM, Chiecchio L, Dagrada G, Konn ZJ, Tapper WJ, et al. Gender disparities in the tumor genetics and clinical outcome of multiple myeloma. Cancer Epidemiol Biomark Prev. 2011;20:1703\u20137.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"1362_CR9","doi-asserted-by":"publisher","first-page":"179","DOI":"10.5306\/wjco.v14.i4.179","volume":"14","author":"AI Bangolo","year":"2023","unstructured":"Bangolo AI, Fwelo P, Trivedi C, Sagireddy S, Aljanaahi H, Auda A, et al. Interaction between age and gender on survival outcomes in extramedullary multiple myeloma over the past two decades. World J Clin Oncol. 2023;14:179\u201389.","journal-title":"World J Clin Oncol"},{"key":"1362_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-65590-4","volume":"14","author":"DT Zhu","year":"2024","unstructured":"Zhu DT, Park A, Lai A, Zhang L, Attar H, Rebbeck TR. Multiple myeloma incidence and mortality trends in the United States, 1999\u20132020. Sci Rep. 2024;14:14564.","journal-title":"Sci Rep"},{"key":"1362_CR11","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.clml.2021.04.013","volume":"21","author":"S Bird","year":"2021","unstructured":"Bird S, Cairns D, Menzies T, Boyd K, Davies F, Cook G, et al. Sex differences in multiple myeloma biology but not clinical outcomes: results from 3894 patients in the Myeloma XI Trial. Clin Lymphoma Myeloma Leuk. 2021;21:667\u201375.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1362_CR12","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1038\/nrg3074","volume":"12","author":"M Esteller","year":"2011","unstructured":"Esteller M. Non-coding RNAs in human disease. Nat Rev Genet. 2011;12:861\u201374.","journal-title":"Nat Rev Genet"},{"key":"1362_CR13","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/S0092-8674(04)00045-5","volume":"116","author":"DP Bartel","year":"2004","unstructured":"Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. cell. 2004;116:281\u201397.","journal-title":"cell"},{"key":"1362_CR14","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/nrg2521","volume":"10","author":"TR Mercer","year":"2009","unstructured":"Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: insights into functions. Nat Rev Genet. 2009;10:155\u20139.","journal-title":"Nat Rev Genet"},{"key":"1362_CR15","doi-asserted-by":"publisher","first-page":"68","DOI":"10.3390\/ncrna9060068","volume":"9","author":"NH Ismail","year":"2023","unstructured":"Ismail NH, Mussa A, Al-Khreisat MJ, Mohamed Yusoff S, Husin A, Al-Jamal HAN, et al. Dysregulation of non-coding RNAs: roles of miRNAs and lncRNAs in the pathogenesis of multiple myeloma. Non Coding RNA. 2023;9:68.","journal-title":"Non Coding RNA"},{"key":"1362_CR16","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1182\/blood.2021014749","volume":"140","author":"E Menu","year":"2022","unstructured":"Menu E, Vanderkerken K. Exosomes in multiple myeloma: from bench to bedside. Blood. 2022;140:2429\u201342.","journal-title":"Blood"},{"key":"1362_CR17","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1002\/path.4712","volume":"239","author":"J Wang","year":"2016","unstructured":"Wang J, De Veirman K, Faict S, Frassanito MA, Ribatti D, Vacca A, et al. Multiple myeloma exosomes establish a favourable bone marrow microenvironment with enhanced angiogenesis and immunosuppression. J Pathol. 2016;239:162\u201373.","journal-title":"J Pathol"},{"key":"1362_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0139-7","volume":"8","author":"S Faict","year":"2018","unstructured":"Faict S, Muller J, De Veirman K, De Bruyne E, Maes K, Vrancken L, et al. Exosomes play a role in multiple myeloma bone disease and tumor development by targeting osteoclasts and osteoblasts. Blood Cancer J. 2018;8:105.","journal-title":"Blood Cancer J"},{"key":"1362_CR19","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1172\/JCI66517","volume":"123","author":"AM Roccaro","year":"2013","unstructured":"Roccaro AM, Sacco A, Maiso P, Azab AK, Tai YT, Reagan M, et al. BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. J Clin Invest. 2013;123:1542\u201355.","journal-title":"J Clin Invest"},{"key":"1362_CR20","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1182\/blood-2014-03-562439","volume":"124","author":"J Wang","year":"2014","unstructured":"Wang J, Hendrix A, Hernot S, Lemaire M, De Bruyne E, Van Valckenborgh E, et al. Bone marrow stromal cell\u2013derived exosomes as communicators in drug resistance in multiple myeloma cells. Blood. 2014;124:555\u201366.","journal-title":"Blood"},{"key":"1362_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:1\u201321.","journal-title":"Genome Biol"},{"key":"1362_CR22","doi-asserted-by":"crossref","unstructured":"Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B. 1995;57:289\u2013300.","DOI":"10.1111\/j.2517-6161.1995.tb02031.x"},{"key":"1362_CR23","doi-asserted-by":"publisher","first-page":"D919","DOI":"10.1093\/nar\/gkad1008","volume":"52","author":"G Zhang","year":"2023","unstructured":"Zhang G, Song C, Fan S, Yin M, Wang X, Zhang Y, et al. LncSEA 2.0: an updated platform for long non-coding RNA related sets and enrichment analysis. Nucleic Acids Res. 2023;52:D919\u2013D28.","journal-title":"Nucleic Acids Res"},{"key":"1362_CR24","first-page":"D148","volume":"48","author":"H-Y Huang","year":"2019","unstructured":"Huang H-Y, Lin Y-C-D, Li J, Huang K-Y, Shrestha S, Hong H-C, et al. miRTarBase 2020: updates to the experimentally validated microRNA\u2013target interaction database. Nucleic Acids Res. 2019;48:D148\u2013D54.","journal-title":"Nucleic Acids Res"},{"key":"1362_CR25","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1111\/cas.15275","volume":"113","author":"C Lv","year":"2022","unstructured":"Lv C, Sun J, Ye Y, Lin Z, Li H, Liu Y, et al. Long noncoding RNA EIF1AX-AS1 promotes endometrial cancer cell apoptosis by affecting EIF1AX mRNA stabilization. Cancer Sci. 2022;113:1277\u201391.","journal-title":"Cancer Sci"},{"key":"1362_CR26","doi-asserted-by":"crossref","unstructured":"Alaterre E, Raimbault S, Goldschmidt H, Bouhya S, Requirand G, Robert N, et al. CD24, CD27, CD36 and CD302 gene expression for outcome prediction in patients with multiple myeloma. Oncotarget. 2017;8:98931\u201344.","DOI":"10.18632\/oncotarget.22131"},{"key":"1362_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00589-y","volume":"11","author":"T Mori","year":"2021","unstructured":"Mori T, Verma R, Nakamoto-Matsubara R, Siu KT, Panaroni C, Fulzele KS, et al. Low NCOR2 levels in multiple myeloma patients drive multidrug resistance via MYC upregulation. Blood Cancer J. 2021;11:194.","journal-title":"Blood Cancer J"},{"key":"1362_CR28","doi-asserted-by":"crossref","unstructured":"Cippitelli M, Stabile H, Kosta A, Petillo S, Lucantonio L, Gismondi A, et al. Role of NF-\u03baB signaling in the interplay between multiple myeloma and mesenchymal stromal cells. Int J Mol Sci. 2023;24:1823.","DOI":"10.3390\/ijms24031823"},{"key":"1362_CR29","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1158\/2326-6066.CIR-14-0112","volume":"2","author":"Y Xia","year":"2014","unstructured":"Xia Y, Shen S, Verma IM. NF-\u03baB, an active player in human cancers. Cancer Immunol Res. 2014;2:823\u201330.","journal-title":"Cancer Immunol Res"},{"key":"1362_CR30","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/sj.bjc.6605530","volume":"102","author":"Y Wu","year":"2010","unstructured":"Wu Y, Zhou BP. TNF-alpha\/NF-kappaB\/Snail pathway in cancer cell migration and invasion. Br J Cancer. 2010;102:639\u201344.","journal-title":"Br J Cancer"},{"key":"1362_CR31","doi-asserted-by":"publisher","first-page":"16","DOI":"10.15698\/cst2025.05.304","volume":"9","author":"A Dom\u00ednguez-L\u00f3pez","year":"2025","unstructured":"Dom\u00ednguez-L\u00f3pez A, Maga\u00f1a-Guerrero FS, Buentello-Volante B, Vivanco-Rojas \u00d3, Garfias Y. NFAT5: a stress-related transcription factor with multiple functions in health and disease. Cell Stress. 2025;9:16\u201348.","journal-title":"Cell Stress"},{"key":"1362_CR32","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1182\/blood.2024025690","volume":"145","author":"R Nair","year":"2025","unstructured":"Nair R, Vu AH, Freer AK, Bhatia KS, Wang D, Savani MR, et al. Heme promotes venetoclax resistance in multiple myeloma through MEK-ERK signaling and purine biosynthesis. Blood. 2025;145:732\u201347.","journal-title":"Blood"},{"key":"1362_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s13008-025-00143-3","volume":"20","author":"T R\u016f\u017ei\u010dkov\u00e1","year":"2025","unstructured":"R\u016f\u017ei\u010dkov\u00e1 T, Vlachov\u00e1 M, Pe\u010dinka L, Brychtov\u00e1 M, Ve\u010de\u0159a M, Radov\u00e1 L, et al. Detection of early relapse in multiple myeloma patients. Cell Div. 2025;20:4.","journal-title":"Cell Div"},{"key":"1362_CR34","doi-asserted-by":"publisher","first-page":"3877","DOI":"10.3390\/cancers13153877","volume":"13","author":"A-M Papanota","year":"2021","unstructured":"Papanota A-M, Tsiakanikas P, Kontos CK, Malandrakis P, Liacos C-I, Ntanasis-Stathopoulos I, et al. A molecular signature of circulating MicroRNA can predict osteolytic bone disease in multiple myeloma. Cancers. 2021;13:3877.","journal-title":"Cancers"},{"key":"1362_CR35","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1186\/s13046-024-03197-3","volume":"43","author":"V Di Paolo","year":"2024","unstructured":"Di Paolo V, Paolini A, Galardi A, Gasparini P, De Cecco L, Colletti M, et al. Plasma-derived extracellular vesicles miR-335\u20135p as potential diagnostic biomarkers for fusion-positive rhabdomyosarcoma. J Exp Clin Cancer Res. 2024;43:282.","journal-title":"J Exp Clin Cancer Res"},{"key":"1362_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2021.785185","volume":"12","author":"P Tang","year":"2021","unstructured":"Tang P, Qu W, Wang T, Liu M, Wu D, Tan L, et al. Identifying a hypoxia-related long non-coding RNAs signature to improve the prediction of prognosis and immunotherapy response in hepatocellular carcinoma. Front Genet. 2021;12:785185.","journal-title":"Front Genet"},{"key":"1362_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110852","volume":"124","author":"Y Wan","year":"2023","unstructured":"Wan Y, Jiang J, Chen M, Han X, Zhong L, Xiao F, et al. Unravelling the imbalanced Th17-like cell differentiation by single-cell RNA sequencing in multiple myeloma. Int Immunopharmacol. 2023;124:110852.","journal-title":"Int Immunopharmacol"},{"key":"1362_CR38","doi-asserted-by":"publisher","first-page":"3796","DOI":"10.3390\/cancers14153796","volume":"14","author":"R Herv\u00e1s-Salcedo","year":"2022","unstructured":"Herv\u00e1s-Salcedo R, Mart\u00edn-Antonio B. A journey through the inter-cellular interactions in the bone marrow in multiple myeloma: implications for the next generation of treatments. Cancers. 2022;14:3796.","journal-title":"Cancers"},{"key":"1362_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.semdp.2025.150916","volume":"42","author":"L Wang","year":"2025","unstructured":"Wang L, Shi M, Sung AY, Yin CC, Bai Y, Chen M. Role of the bone marrow microenvironment in multiple myeloma: Impact of niches on drug resistance mechanisms. Semin Diagn Pathol. 2025;42:150916.","journal-title":"Semin Diagn Pathol"},{"key":"1362_CR40","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1002\/1878-0261.13564","volume":"18","author":"PL Theard","year":"2024","unstructured":"Theard PL, Linke AJ, Sealover NE, Daley BR, Yang J, Cox K, et al. SOS2 modulates the threshold of EGFR signaling to regulate osimertinib efficacy and resistance in lung adenocarcinoma. Mol Oncol. 2024;18:641\u201361.","journal-title":"Mol Oncol"},{"key":"1362_CR41","doi-asserted-by":"crossref","unstructured":"Baltan\u00e1s FC, Garc\u00eda-Navas R, Santos E. SOS2 comes to the fore: differential functionalities in physiology and pathology. Int J Mol Sci. 2021;22:6613.","DOI":"10.3390\/ijms22126613"},{"key":"1362_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-53399-0","volume":"14","author":"W Yang","year":"2024","unstructured":"Yang W, Lin L, Lu T, Yu H, Zhang S. Identification of EMT-associated prognostic features among grade II\/III gliomas. Sci Rep. 2024;14:2822.","journal-title":"Sci Rep"},{"key":"1362_CR43","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1038\/s41388-019-1037-6","volume":"39","author":"Y Xie","year":"2020","unstructured":"Xie Y, Liu J, Jiang H, Wang J, Li X, Wang J, et al. Proteasome inhibitor induced SIRT1 deacetylates GLI2 to enhance hedgehog signaling activity and drug resistance in multiple myeloma. Oncogene. 2020;39:922\u201334.","journal-title":"Oncogene"},{"key":"1362_CR44","first-page":"9932","volume":"13","author":"Y Yuan","year":"2021","unstructured":"Yuan Y, Guo M, Gu C, Yang Y. The role of Wnt\/\u03b2-catenin signaling pathway in the pathogenesis and treatment of multiple myeloma (review). Am J Transl Res. 2021;13:9932\u201349.","journal-title":"Am J Transl Res"},{"key":"1362_CR45","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13045-018-0615-3","volume":"11","author":"I Spaan","year":"2018","unstructured":"Spaan I, Raymakers RA, van de Stolpe A, Peperzak V. Wnt signaling in multiple myeloma: a central player in disease with therapeutic potential. J Hematol Oncol. 2018;11:67.","journal-title":"J Hematol Oncol"},{"key":"1362_CR46","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1038\/s41375-019-0404-1","volume":"33","author":"H van Andel","year":"2019","unstructured":"van Andel H, Kocemba KA, Spaargaren M, Pals ST. Aberrant Wnt signaling in multiple myeloma: molecular mechanisms and targeting options. Leukemia. 2019;33:1063\u201375.","journal-title":"Leukemia"},{"key":"1362_CR47","doi-asserted-by":"crossref","unstructured":"Mikulski D, Ko\u015bcielny K, Dr\u00f3\u017cd\u017c I, Mirocha G, Nowicki M, Misiewicz M, et al. Serum levels of miR-122-5p and miR-125a-5p predict hepatotoxicity occurrence in patients undergoing autologous hematopoietic stem cell transplantation. Int J Mol Sci. 2024;25:4355.","DOI":"10.3390\/ijms25084355"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01362-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01362-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01362-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T12:13:04Z","timestamp":1760616784000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01362-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,16]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1362"],"URL":"https:\/\/doi.org\/10.1038\/s41408-025-01362-1","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,16]]},"assertion":[{"value":"19 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"162"}}